These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 31479925)

  • 21. Feline comorbidities: Recognition, diagnosis and management of the cushingoid diabetic.
    Cook AK; Evans JB
    J Feline Med Surg; 2021 Jan; 23(1):4-16. PubMed ID: 33403912
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison between a flash glucose monitoring system and a portable blood glucose meter for monitoring dogs with diabetes mellitus.
    Del Baldo F; Canton C; Testa S; Swales H; Drudi I; Golinelli S; Fracassi F
    J Vet Intern Med; 2020 Nov; 34(6):2296-2305. PubMed ID: 33124730
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Examining the Potential Applicability of Orexigenic and Anorexigenic Peptides in Veterinary Medicine for the Management of Obesity in Companion Animals.
    Osiak-Wicha C; Kras K; Tomaszewska E; Muszyński S; Arciszewski MB
    Curr Issues Mol Biol; 2024 Jul; 46(7):6725-6745. PubMed ID: 39057043
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Advances in Drug Treatments for Companion Animal Obesity.
    Zomer HD; Cooke PS
    Biology (Basel); 2024 May; 13(5):. PubMed ID: 38785817
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug release profile of a novel exenatide long-term drug delivery system (OKV-119) administered to cats.
    Klotsman M; Anderson WH; Gilor C
    BMC Vet Res; 2024 May; 20(1):211. PubMed ID: 38762728
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diabetes Technology and Pets: A Market of the Future?
    Heinemann L
    J Diabetes Sci Technol; 2024 Mar; 18(2):255-256. PubMed ID: 37431952
    [No Abstract]   [Full Text] [Related]  

  • 27. Physiological and pharmacological actions of glucagon like peptide-1 (GLP-1) in domestic animals.
    Model JFA; Rocha DS; Fagundes ADC; Vinagre AS
    Vet Anim Sci; 2022 Jun; 16():100245. PubMed ID: 35372707
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fighting type 2 diabetes: Formulation strategies for peptide-based therapeutics.
    Bendicho-Lavilla C; Seoane-Viaño I; Otero-Espinar FJ; Luzardo-Álvarez A
    Acta Pharm Sin B; 2022 Feb; 12(2):621-636. PubMed ID: 35256935
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety, Tolerability, and Proof-Of-Concept Study of OKV-119, a Novel Exenatide Long-Term Drug Delivery System, in Healthy Cats.
    Klotsman M; Adin CA; Anderson WH; Gilor C
    Front Vet Sci; 2021; 8():661546. PubMed ID: 34046446
    [No Abstract]   [Full Text] [Related]  

  • 30. Advances in Subcutaneous Delivery Systems of Biomacromolecular Agents for Diabetes Treatment.
    Li C; Wan L; Luo J; Jiang M; Wang K
    Int J Nanomedicine; 2021; 16():1261-1280. PubMed ID: 33628020
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Glycemic variability in newly diagnosed diabetic cats treated with the glucagon-like peptide-1 analogue exenatide extended release.
    Krämer AL; Riederer A; Fracassi F; Boretti FS; Sieber-Ruckstuhl NS; Lutz TA; Contiero B; Zini E; Reusch CE
    J Vet Intern Med; 2020 Nov; 34(6):2287-2295. PubMed ID: 33001499
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and efficacy assessment of a GLP-1 mimetic: insulin glargine combination for treatment of feline diabetes mellitus.
    Scuderi MA; Ribeiro Petito M; Unniappan S; Waldner C; Mehain S; McMillian CJ; Snead EC
    Domest Anim Endocrinol; 2018 Oct; 65():80-89. PubMed ID: 30015124
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Exendin-4 from Heloderma suspectum venom: From discovery to its latest application as type II diabetes combatant.
    Yap MKK; Misuan N
    Basic Clin Pharmacol Toxicol; 2019 May; 124(5):513-527. PubMed ID: 30417596
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same?
    Gentilella R; Pechtner V; Corcos A; Consoli A
    Diabetes Metab Res Rev; 2019 Jan; 35(1):e3070. PubMed ID: 30156747
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A once-monthly GLP-1 receptor agonist for treatment of diabetic cats.
    Schneider EL; Reid R; Parkes DG; Lutz TA; Ashley GW; Santi DV
    Domest Anim Endocrinol; 2020 Jan; 70():106373. PubMed ID: 31479925
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Hydrogel-Microsphere Drug Delivery System That Supports Once-Monthly Administration of a GLP-1 Receptor Agonist.
    Schneider EL; Hearn BR; Pfaff SJ; Reid R; Parkes DG; Vrang N; Ashley GW; Santi DV
    ACS Chem Biol; 2017 Aug; 12(8):2107-2116. PubMed ID: 28605180
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacology of the glucagon-like peptide-1 analog exenatide extended-release in healthy cats.
    Rudinsky AJ; Adin CA; Borin-Crivellenti S; Rajala-Schultz P; Hall MJ; Gilor C
    Domest Anim Endocrinol; 2015 Apr; 51():78-85. PubMed ID: 25594949
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.